2025
SJR Q2
JCR Q2 · 3,4
31 matched articles
SCIE
Journal detail
Expert Opinion on Pharmacotherapy
- Publisher
- Taylor and Francis Ltd.
- Country
- United Kingdom · Western Europe
- Type
- journal
- ISSN
-
1465656617447666
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,765
- Quartile Q2
- H-Index 104
- Cites/doc 3,14
- Docs (3y) 617
- Cites (3y) 1.703
Clarivate
Web of Science · JCR · 2025
- JCR Q Q2
- JIF 3,4
- 5Y JIF 3
- JCI 0,52
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Medicine (miscellaneous) Q2
- Pharmacology Q2
- Pharmacology (medical) Q2
Areas
- Medicine
- Pharmacology, Toxicology and Pharmaceutics
WoS categories
- Pharmacology & Pharmacy
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | Q2 | 0,765 | 3,4 | 3 | 0,52 | Q3 | 104 |
| 2024 | Q2 | Q2 | 0,672 | 2,7 | 3 | 0,49 | Q3 | 99 |
| 2023 | Q2 | Q3 | 0,687 | 2,5 | 3,3 | 0,52 | Q3 | 99 |
| 2022 | Q2 | Q3 | 0,702 | 3,2 | 3,1 | 0,53 | Q3 | 99 |
| 2021 | Q2 | Q2 | 0,735 | 4,1 | 3,5 | 0,51 | Q3 | 99 |
| 2020 | Q2 | Q2 | 0,873 | 3,9 | 3,4 | 0,5 | Q3 | 99 |
| 2019 | Q2 | Q2 | 0,742 | 2,9 | 2,7 | 0,5 | Q3 | 99 |
| 2018 | — | Q2 | — | 3 | 3 | 0,55 | Q3 | — |
| 2017 | Q1 | Q2 | 0,909 | 3,5 | 3,1 | 0,59 | Q3 | 99 |
| 2016 | Q1 | Q1 | 1,014 | 3,9 | 3,2 | — | — | 99 |
| 2015 | Q1 | Q1 | 0,907 | 3,5 | 2,9 | — | — | 99 |
| 2014 | Q2 | Q1 | 0,764 | 3,5 | 2,8 | — | — | 99 |
| 2013 | Q2 | Q2 | 0,793 | 3,1 | 2,5 | — | — | 99 |
| 2012 | Q2 | Q2 | 0,756 | 2,9 | 2,2 | — | — | 99 |
| 2011 | Q1 | Q2 | 0,8 | 3,2 | 2,2 | — | — | 99 |
| 2010 | Q2 | Q2 | 0,66 | 2,4 | 1,9 | — | — | 99 |
| 2009 | — | Q3 | — | 2 | 1,7 | — | — | — |
| 2008 | — | Q3 | — | 2,1 | 1,8 | — | — | — |
| 2007 | — | Q3 | — | 1,7 | — | — | — | — |
| 2006 | — | Q3 | — | 1,7 | — | — | — | — |
| 2005 | — | Q3 | — | 1,8 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 143/356 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 164/352 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 180/354 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 146/278 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 109/279 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 117/276 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 122/271 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 98/267 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 66/261 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 48/257 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 59/255 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 60/255 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 70/256 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 84/261 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 67/261 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 120/252 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 139/237 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 126/219 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 127/205 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 112/199 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 100/193 |